❌

Reading view

Don't Retrain, Just Reuse: Recovering Dual-Target Molecules from Single-Target Diffusion Models

arXiv:2605.25681v1 Announce Type: cross Abstract: Designing a single molecule that modulates two targets is a promising strategy for polypharmacology, but it remains substantially harder than standard single-target generation because one candidate must satisfy two binding requirements while preserving drug-likeness and synthesizability. Existing dual-target generative methods typically introduce dual-target capability by either retraining the generator or intervening in the diffusion process during sampling. The former can be costly and difficult to stabilize when dual-target supervision is sparse, while the latter may be sensitive to denoising-time target balancing and competing update directions. These limitations motivate a generator-preserving alternative that keeps the pretrained prior intact: can dual-target candidates instead be recovered from the input space of a frozen single-target diffusion model, without modifying its parameters or denoising dynamics? We formulate this task as a constrained multi-objective optimization problem and propose REUSE, a hierarchical evolutionary input-space search framework that combines pair-conditioned exploration with structured multi-stage selection to enforce dual-target affinity, chemical quality, and diversity. Experiments show that, compared with methods that modify the diffusion process, REUSE consistently improves dual-target affinity and balance, achieving a 20.9-percentage-point gain in Dual High Affinity over the strongest prior baseline while maintaining competitive molecular quality.
  •  

Filaggrin as a potential biomarker in gastric cancer: insights from multi-omics analysis and experimental validation

Front Immunol. 2026 May 8;17:1742982. doi: 10.3389/fimmu.2026.1742982. eCollection 2026.

ABSTRACT

BACKGROUND: Filaggrin (FLG) plays an important role in the progression of malignant tumors; however, its expression characteristics and biological functions in gastric cancer (GC) remain unclear.

METHODS: Cancer-related datasets were retrieved from public repositories, including the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). A competing endogenous RNA (ceRNA) network was constructed to explore potential regulatory networks involving FLG. Differential expression analysis, genetic alteration analysis, and clinicopathological and survival analyses were performed to evaluate the role of FLG in GC. In addition, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and in vitro functional experiments were conducted to investigate the biological effects and potential mechanisms of FLG in GC.

RESULTS: FLG was aberrantly expressed across multiple cancer types and was significantly associated with clinical characteristics and prognosis in GC. Further analyses showed that FLG was involved in genetic alterations and was closely associated with the immune microenvironment in GC. Functional experiments demonstrated that FLG promoted the invasion and metastasis of GC cells. Mechanistically, GSEA and experimental validation indicated that FLG exerted its tumor-promoting effects, at least in part, through activation of the epithelial-mesenchymal transition (EMT) signaling pathway.

CONCLUSION: This study clarifies the biological role of FLG in GC and highlights its potential as a novel prognostic biomarker and therapeutic target. These findings provide new insights into the molecular mechanisms underlying GC progression and may contribute to the development of more effective diagnostic and therapeutic strategies.

PMID:42183248 | PMC:PMC13194527 | DOI:10.3389/fimmu.2026.1742982

  •  

Filaggrin as a potential biomarker in gastric cancer: insights from multi-omics analysis and experimental validation

Front Immunol. 2026 May 8;17:1742982. doi: 10.3389/fimmu.2026.1742982. eCollection 2026.

ABSTRACT

BACKGROUND: Filaggrin (FLG) plays an important role in the progression of malignant tumors; however, its expression characteristics and biological functions in gastric cancer (GC) remain unclear.

METHODS: Cancer-related datasets were retrieved from public repositories, including the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). A competing endogenous RNA (ceRNA) network was constructed to explore potential regulatory networks involving FLG. Differential expression analysis, genetic alteration analysis, and clinicopathological and survival analyses were performed to evaluate the role of FLG in GC. In addition, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and in vitro functional experiments were conducted to investigate the biological effects and potential mechanisms of FLG in GC.

RESULTS: FLG was aberrantly expressed across multiple cancer types and was significantly associated with clinical characteristics and prognosis in GC. Further analyses showed that FLG was involved in genetic alterations and was closely associated with the immune microenvironment in GC. Functional experiments demonstrated that FLG promoted the invasion and metastasis of GC cells. Mechanistically, GSEA and experimental validation indicated that FLG exerted its tumor-promoting effects, at least in part, through activation of the epithelial-mesenchymal transition (EMT) signaling pathway.

CONCLUSION: This study clarifies the biological role of FLG in GC and highlights its potential as a novel prognostic biomarker and therapeutic target. These findings provide new insights into the molecular mechanisms underlying GC progression and may contribute to the development of more effective diagnostic and therapeutic strategies.

PMID:42183248 | PMC:PMC13194527 | DOI:10.3389/fimmu.2026.1742982

  •  
❌